Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Dr. Mark Freedman interviewed about experimental mesenchymal stem cell treatment for multiple sclerosis
November 16, 2008
Dr. Mark Freedman was
interviewed on CTV National News
about an experimental stem cell treatment that researchers in Israel are offering to multiple sclerosis (MS) patients. The treatment involves mesenchymal stem cells, one of the three types of stem cells found in adult bone marrow.
Dr. Freedman noted that some patients seem to have improved after receiving this therapy, but much more research is needed to determine if it is safe and effective. Dr. Freedman is organizing an international meeting to discuss this and he hopes to eventually begin a clinical trial in Canada.
Dr. Freedman and colleague Dr. Harry Atkins are currently leading a clinical trial that is examining another type of bone marrow stem cell transplant for MS. This trial uses strong chemotherapy and “hematopoetic” stem cells to replace the damaged immune system with a new one. More information about this trial is available on the
MS Society of Canada’s website
. The
Stem Cell Network
also provides general information on stem cell research for MS.
Patients interested in experimental therapies for MS should speak with their specialists.